cyrilzakka/clinical-trials huggingface dataset:
Effects of Co-treatment on Endometrial abv3-integrin Expressions in Women With Recurrent Implantation Failure

To compare the abv3-integrin expression in endometrium tissue among RIF women between the GnRH analogue with Aromatase Inhibitor (Group A) , GnRH analogue with progesterone (Group B) and GnRH analogue alone as control group (Group C)

i. To determine the abv3-integrin expression isolated from endometrium tissue from women with RIF prior to medical therapy.

ii. To determine the abv3-integrin expression isolated from endometrium tissue from Group A, Group B and Group C following the medical therapy.

iii. To compare the abv3-integrin expression from endometrium tissue obtained from Group A, B and C following the medical therapy.

iv. To compare the implantation rates among Group A, B and C following the medical therapy.

v. To compare the ongoing pregnancy among Group A, B and C following the medical therapy

Eligibility Criteria:
Inclusion Criteria:

* Women of 18 to 40 years of age
* No significant pre-existing major medical.
* Diagnosed as recurrent implantation failure - at least two or more failure of achieving pregnancy following embryo transfer (ET) despite the optimum endometrial thickness and good quality of embryo (unexplained).
* Regular menstrual cycle atleast 3 months prior to treatment
* Not taking any hormonal treatment for atlest 3months prior to recruitment
* Agreed to participate

Exclusion Criteria:

* Concurrent significant pre-existing major medical conditions such as uncontrolled diabetes, active systemic lupus erythematosus (SLE) or Anti Phospholipid Syndrome (APS) that will interfere with implantation.
* Poor quality of embryo
* Suboptimal endometrial thickness(\<8mm) during the embryo transfer (ET).
* On hormonal therapy prior to recruitment.
* Not agreed to participate
Role of K+ and Ca2+ in Development of Muscle Fatigue

The aim of the study is to investigate the role of K+ and Ca2+ in development of muscle fatigue in trained young men.


Eligibility Criteria:
Inclusion Criteria:

* physical active healthy men
* aged 18-40 years

Exclusion Criteria:

* smokers
* allergy towards terbutaline
* chronic disease
Post-market Clinical Study to Confirm Safety and Performance of PuraStat® for the Management of Bleeding in Vascular Surgery.

The objective of this post-market clinical follow-up study is to collect medical information on patients implanted with PuraStat®, according to each participating institution's procedures and standards of care.

This multicentre, single arm post-market clinical study aims to collect medical information on patients implanted with PuraStat®, Absorbable Haemostatic Material, according to each participating institution's procedures and standards of care for confirming the safety and the performance of PuraStat®, for the management of bleeding in vascular surgery (Carotid Endarterectomy either by direct closure (without the use of patch), or by patch reconstruction or eversion technique).

Eligibility Criteria:
Main Inclusion criteria:

1. Male or female patient ≥18 years old
2. Subject undergoing elective carotid endarterectomy
3. Subject who is able to give voluntary, written informed consent to participate in this clinical study and from whom consent has been obtained
4. Subject, who, in the opinion of the Clinical Investigator, is able to understand this clinical study, cooperate with the study procedures and is willing to return for the required post-treatment follow-up
5. Intra-operative inclusion criteria: Subject requiring the use of PuraStat® for haemostasis during elective carotid endarterectomy either by direct closure (without the use of patch), or by patch reconstruction or eversion technique when haemostasis by ligation or standard means is insufficient or impractical.

Main exclusion criteria:

1. Presence or sequelae of coagulation disorder
2. Known allergy or hypersensitivity to any component of PuraStat®
3. Concurrent participation in another clinical trial with a medical device or a medicinal product
4. Pregnant or interested in becoming pregnant during the duration of the study, or breast feeding

   Intra-operative exclusion criteria:
5. Spurting and/or gushing haemorrhage site(s)
6. Contaminated or potentially contaminated surgical area
7. Fibrin glue and/or topical haemostatic agent used before or concomitantly to the use of PuraStat®
8. Persistent major bleeding after conventional haemostasis
Impact of Hypnosis on Pain Management During Dialysis on Patients Suffering From Arterial Disease

A chronic renal disease can results in the development of cardiovascular complications, including chronic arterial disease ; but a cardiovascular disease may be from a kidney malfunction that will end in end stage renal disease (ESRD). Two thirds of the chronic hemodialysis patients taken in charge in Grenoble in the last years suffered from an arterial disease at a symptomatic stage. Breakthrough pain can appear during the hemodialysis sessions. These sessions induce sudden hemodynamic changes and a peripheral vasoconstriction reaction that increases in particular all pain phenomena related to chronic low limbs ischemia. Therefore, patients have to face pain, sometimes chronic but also breakthrough pain, during the dialysis sessions, in all its dimensions.

The analgesic balance through the classical drug treatment is extremely complex, as they are both at risk of overdose and of partial effectiveness. Strict medical treatment remains unsatisfactory, as it takes into account only the expressions of symptoms during dialysis sessions, when most of the time pain is already installed and analgesic treatment is not completely effective.

The combination of classic pharmacological treatment with hypnosis, already used in other indications (chronic pain, analgesia, depression and anxiety), may mitigate the painful feeling on patients suffering from arterial disease during the dialysis sessions, with a beneficial impact on their overall quality of life. There is also evidence to suggest that hypnosis may be more effective treating neuropathic or vascular pain, those experienced by our patients, than musculoskeletal pain, like back pain.

Hypnosis is a mind-body approach focused on the subject, and not on the disease or the act of dialysis. It can be described at the same time as a modified state of consciousness and a particular intersubjective relation between a practitioner and his patient. The practice of this kind of hypnoanalgesia by the nurses is particularly relevant in hemodialysis, as the trust developed during regular chronic treatment can become an asset to shorten the induction phase and help to install this intersubjective relation.

The high incidence of this complication, the difficulties of current pain management and the impact on everyday life for the patients, justify the choice of this approach, where more further research is needed.


Eligibility Criteria:
Inclusion Criteria:

* Chronic hemodialysis patients, requiring dialysis at least 3 times per week.
* Patients rating pain on a Visual analogue scale (VAS) \> or = to 3 during hemodialysis sessions for lower limb pain related to chronic arterial disease.
* Patients affiliated to a health insurance company.
* Patients having consented to participate in the study.

Exclusion Criteria:

* Minors.
* Patients protected by law (under guardianship, deprived of liberty ...).
* Pregnant women.
* Refusal
* Patients not understanding French.
* Patients with cognitive, psychotic or behavioral disorders.
* Patients with a hearing loss limiting communication.
To Study the Effects of Cordyceps Cicadae on Vision Care

Cordyceps cicadae is a traditional Asian herbal medicine with a variety of bioactive substances and curative effects similar to Cordyceps Cicadae, and it has been reported that anti-dry eye and eye protection ingredients can be extracted. With the advancement of civilization, the number of patients with high myopia is increasing year by year and suffers from complications of dry eye or other eye diseases. In this study, the subjects were provided with cicadae extract or placebo in a double-blind manner, tracked the degree of visual fatigue by regular questionnaires, and measured for visual acuity, axial length and diopter. The purpose of this study is to investigate the effect of cicadae extract on visual acuity and visual fatigue, and to evaluate its potential as a health food ingredient.

1. Visual acuity measurement: Snellen's Chart was used to measure visual acuity.
2. Refractive examination: Measure binocular refraction with Open Field computer refractor (Shin-Nippon Nvision K5001 Wide View).
3. Measuring the axial length of the eye: Use the multifunctional optical eyeball length measuring instrument (Lenstar) to measure the distance from the instrument to the optical paths such as the cornea, lens, and retina, and then convert to the axial length of the eye.
4. Corneal radian measurement: Use a keratometer (Bausch \& Lomb Keratometer) to measure the corneal radian and curvature, and estimate the degree of corneal astigmatism.
5. Visual fatigue questionnaire survey: A visual fatigue scale questionnaire was designed using Ocular Surface Disease Index (OSDI) and Computer Vision Syndrome (CVS).

Eligibility Criteria:
Inclusion Criteria:

1. Adults aged 20 or over
2. Willing to participate in this study and sign the subject's consent form
3. Myopia less than 700 degrees

Exclusion Criteria:

1. Have consumed related eye care products in past 3 months
2. Those who have eye infection in the past 3 months
3. People who have been diagnosed with any eye diseases in past 3 months
4. Those who are allergic to cicadae
CONNACT OA Knee Cohort

CONNACT OA knee cohort is a prospective longitudinal cohort study where we aim to collect sociodemographic, psychosocial, clinical, health utilization and cost data in order to better understand the Asian OA knee cohort and investigate for prognostic variables that can potentially influence a patients clinical outcome and treatment decisions.

In addition, the CONNACT OA knee cohort will form the basis for a cohort multiple randomized control trial (cmRCT) study design where multiple interventions can be tested in a randomized fashion. Each intervention is offered to a randomly selected sample of patients eligible for that intervention, who are then compared with the rest of the eligible patients from the cohort that are still being treated as usual.


Eligibility Criteria:
Inclusion Criteria:

1. Knee Osteoarthritis (based on NICE guidelines)
2. Age \> 45 years
3. Community ambulator with or without walking aid
4. Conversant in English or Chinese

Exclusion Criteria:

1. Alternative diagnosis to Knee OA e.g. referred pain from spine or hip
2. Other forms of knee arthritis e.g. inflammatory, post-traumatic
3. Moderate to severe cognitive impairment e.g. dementia
4. Previous knee arthroplasty
5. Wheelchair bound patients
6. Medical conditions that will medically interfere with rehabilitation involvement e.g. decompensated heart failure, stroke with significant deficit, end stage renal failure
Percentage Venous Options in Pediatrics & Adults

VeinViewer® Vision will significantly increase the number of peripheral intravenous catheter access targets perceived by clinicians with experience in intravenous cannulation when compared to the number of access targets that these clinicians are able to visualize unaided or to palpate.


Eligibility Criteria:
Pediatric arm

Inclusion Criteria:

* Age 17 years of age or younger,
* Intact skin, without rash,irritation, scarring, open abrasion or other injury in these sites.
* Parent or guardian is English speaking
* Pediatric patients 8 years older will be asked to provide assent
* Participant does not have an acute or critical medical illness or injury requiring immediate evaluation and/or treatment.

Exclusion Criteria:

* 18 years of age or older
* No intact upper extremities
* Patient has had current or recent (within 6 months) venous access in the arm that will be evaluated.
* Acute or critical illness or injury requiring immediate or urgent evaluation and treatment.

Adult arm:

Inclusion Criteria:

* Age 18 years or older,
* At least one intact upper extremity (intact from the base knuckle to the shoulder)
* Intact skin on the dorsum of the hand, the ventral forearm, and antecubital fossa, without rash, irritation, scarring, open abrasion or other injury in these sites.
* Participant does not have an acute or critical medical illness or injury requiring immediate evaluation and/or treatment.

Exclusion Criteria

* Younger than 18 years of age
* No intact upper extremities
* The participant does not have intact skin on the dorsum of the hand, the ventral forearm, and antecubital fossa, without rash, irritation, scarring, open abrasion or other injury preventing appropriate evaluation of these sites.
* Non-English speaking participant.
* Patient has had current or recent (within 6 months) venous access in the arm that will be evaluated.
* Acute or critical illness or injury requiring immediate or urgent evaluation and treatment.
The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease

This study is a prospective, randomized, single-center trial, designed to observe the effect of remote limb ischemic preconditioning on ischemic cerebral vascular disease.


Eligibility Criteria:
Inclusion criteria:

1. Patients with stroke or transient ischemic attack (TIA) within 180 days and the neurologic deficits were well matched to the territory of the stenosed artery, with intracranial arterial stenosis of at least 50% by angiography, at least 70% by ultrasound, or at least 70% by computed tomographic angiography (CTA) or magnetic resonance angiography (MRA)
2. Age between 18 to 80 years old
3. Trial of Org 10172 in Acute Stroke Treatment-1 (TOAST-1) subtype
4. National Institutes of Health Stroke Scale (NIHSS) score 0-15, and Modified Rankin Scale (mRS) score 0-4.
5. ABCD2 score between 6 to 7
6. Stable vital signs, normal hepatic and renal functions,
7. No hemorrhagic tendencies.

Exclusion criteria:

1. Within 72 hrs of intra-artery or intravenous thrombolysis
2. Intracranial hemorrhage or large area of cerebral infarction (more than 1/3 middle cerebral artery perfusion territory)
3. Any soft tissue, orthopedic, or vascular injury, wounds or fractures in extremities which may pose a contraindication for application of the preconditioning cuffs
4. Acute myocardial infarction
5. Systolic blood pressure more than 200 mmHg after drug control
6. Peripheral blood vessel disease
7. Hematologic disease
8. Severe hepatic and renal dysfunction
9. Severe or unstable concomitant disease
10. Cannot tolerate BLIPC or without informed consent
11. Patients who did not complete the whole treatment procedure.
Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.

The FND-R regimen is commonly used in the treatment of indolent Non-Hodgkin's lymphoma (NHL) and contains the chemotherapy agents mitoxantrone, fludarabine, dexamethasone (a steroid) and the monoclonal antibody rituximab. In this trial we are replacing mitoxantrone with pixantrone, an agent with a similar chemical structure (both agents are DNA intercalators). The trial is being run in patients with relapsed or refractory indolent NHL and aims to define the appropriate dose of pixantrone to be used in this combination, as well as to obtain data on pixantrone's safety and activity profile in combination with these drugs.

This trial is expected to recruit up to 30 patients in the USA. Patients will be treated with the drug combination for up to eight months and then followed closely in the four-week period after the last administration. After that, patients will receive physician check-ups every three months.

Eligibility Criteria:
Inclusion criteria

* Patients with relapsed or refractory indolent (low-grade) NHL
* Who have received 1-3 prior treatments with chemotherapy

Exclusion criteria

* Patients previously treated with fludarabine
* Prior treatment with rituximab (Rituxan), unless there was a complete response (CR) or partial response (PR) to that treatment
* Patients known to have an allergic reaction to rituximab, or to murine proteins.
Dose Escalation Safety Study of MM-10-001 in Healthy Subjects

The purpose of this study is to evaluate the safety of increasing doses of MM-10-001 and to determine the dose of MM-10-001 that enhances the immune system in normal healthy subjects.

The drug substance to be studied is a powder produced from shiitake mushroom, containing beta-glucans. The purpose of this study is to evaluate the safety of increasing doses of MM-10-001 and to determine the dose of MM-10-001 that enhances the immune system in normal healthy subjects.

Eligibility Criteria:
Inclusion Criteria:

Healthy subjects of both genders, age \> 45 years old will be eligible for study.

Exclusion Criteria:

Subjects who:

1. Fail to give written informed consent
2. Have BMI over or equal to 30 kg/m2
3. Use corticosteroids (including inhaled steroids) or NSAIDs anti-inflammatory drugs
4. Have uncontrolled hypertension (sitting diastolic blood pressure\>95 mmHg)
5. Have on-going allergy or history of anaphylactic reaction
6. Have on-going allergen specific immunotherapy
7. Are immuno-compromised (HIV infected, cancer and other disease affecting the basal immune response)
8. Have chronic inflammatory disease
9. Have diabetes (type 1 or type 2)
10. Have chronic severe renal disease (creatinine outside normal range)
11. Have chronic severe liver disease (ASAT and/or ALAT more than two times the upper limit of the normal range)
12. Have known cardiac failure
13. Have recently (less than 6 months) experienced myocardial infarction
14. Have gastrointestinal diseases (chronic gastritis, IBD, etc.)
15. Have acute or chronic pancreatitis or impaired pancreatic function, or history of pancreatitis
16. Have been vaccinated within the last three months
17. Eat diet supplement NG24 beta-glucan
18. Eat shiitake cheese
19. Have systemic fungal infection
20. Have any clinical condition that renders them unfit to participate including known/suspected drug or alcohol abuse
21. Do not fully understand the content of the informed consent
22. Pregnant and lactating women or women of childbearing potential not using adequate contraception.
Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer

To improve radiation therapy of prostate cancer, the investigators must be able to accurately identify the tumour. By using advanced functional imaging techniques available on state-of-the-art MRI scanners to clearly show the specific location of the tumour inside the prostate, the investigators can use advanced radiation therapy techniques to specifically target the tumor and control it with as few radiotherapy clinic visits as possible. This is different than current techniques which treat the whole prostate gland to the same dose, delivered over 7-8 weeks of daily radiotherapy visits. By increasing the radiation dose to the active tumor while still maintaining adequate radiation dose to the rest of the prostate, the investigators hope to better control prostate cancer and reduce complications to nearby normal tissues.

This project combines advances in functional imaging of prostate cancer and hypofractionation through stereotactic body radiotherapy (SBRT), with an aim to improve tumour control and reduce or maintain normal tissue complications. The strategy will make use of the combined effectiveness of several functional imaging approaches to identify the dominant lesion(s) within the prostate. An SBRT treatment plan will be designed which utilizes 5 fractions to treat the entire prostate gland with an additional boost to the dominant lesion. The lower dose to the entire prostate should reduce normal tissue complications but still be effective in treating prostate cancer while the increased dose to the dominant lesion should improve tumour control. The use of only 5 fractions will reduce the number of patient visits, thus reducing overall treatment costs.

Eligibility Criteria:
Inclusion Criteria:

* Informed consent
* Age \>18 years
* Histologically confirmed and centrally reviewed prostate adenocarcinoma based
* PSA within 60 days
* High risk prostate cancer defined as any one of: clinical stage \>= T3, Gleason score \>= 8, or PSA \>=20 and \<50 ng/mL.

Exclusion Criteria:

* Evidence of lymph node metastasis
* Evidence of distant metastases
* Prior pelvic radiotherapy or brachytherapy
* Previous radical prostatectomy, cryotherapy, or high-frequency ultrasound
* Unable to undergo gold seed insertion
* Immunosuppressive medications
* Inflammatory bowel disease
* Unable to undergo MRI
* Previous bilateral orchiectomy
* Previous hormonal therapy including LHRH agonists (leuprolide, goserelin), LHRH antagonists (degarelix), anti-androgens (bicalutamide, flutamide, nilutamide), surgical castration, and estrogens
* Previous finasteride within 14 days.
* Previous dutasteride within 180 days.
Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery

This study is a randomized open label study that implies the administration of asprin according to three different regimens.

The aims of the study are:

* to establish whether coronary artery bypass surgery and / or aortic valve replacement surgery with bioprostheses is associated with changes in the rate of platelet regeneration that can reduce the effectiveness of aspirin administered at a dose of 100mg/die in terms of inhibition of platelet biosynthesis of thromboxane A2.
* to determine whether these patients need a different (shorter) interval of administration in order to completely and permanently inhibit the platelet COX-1.

The endpoints of this study are:

- To evaluate the changes in the levels of TXB2 and 12-HETE in serum at 12 and 24 hours after administration of aspirin and the changes in the levels of 11-dehydro TXB2 urinary 8-iso-PGF2 alpha urinary, 2-3 dinor-6-chetoPGF1 alpha, Verify-NOW Aspirin, platelets crosslinked at 12 and 24 hours after administration of aspirin


Eligibility Criteria:
Inclusion Criteria:

* informed consent of the study signed
* coronary artery bypass graft and / or aortic valve replacement surgery with bioprostheses
* age between 55 and 80
* ejection fraction \> 30%.

Exclusion Criteria:

* excessive bleeding (\> 1000mL / 6 h) or the need of re operation for bleeding
* perioperative myocardial infarction
* stroke or renal failure requiring dialysis and need waiting for post-operative anticoagulation
* patients undergoing coronary artery bypass grafting procedure as a consequence of failed percutaneous coronary intervention
* patients undergoing off-pump coronary artery bypass graft
* overt kidney or liver disease
* therapies that influence the coagulation
* fertile women